The RasGEFs SOS1 and SOS2 are Potential Therapeutic Targets in RAS-Driven Cancers
Abstract
The RAS family of genes HRAS, NRAS, and KRAS are mutated in about a third of human cancers, with limited treatment options available. Wild-type RAS isoforms cooperate with mutant RAS to promote oncogenic signaling to downstream effectors, proliferation, and transformation. Activation of wild-type RAS involves the RAS guanine nucleotide exchange factors (RasGEFs) SOS1 and SOS2, creating a dependence on upstream signaling despite constitutive activation of mutant RAS.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 17, 2020
- Accession Number
- AD1182848
Entities
People
- Erin Sheffels
Organizations
- Uniformed Services University of the Health Sciences